Xeltis today announced the completion of Series C financing. The funding round was led by a global strategic investor with participation from venture capital fund Ysios Capital and a number of large private investors. Existing institutional investors (LSP, Kurma Partners and VI Partners) and private investors also participated in the financing.
This is the largest investment round for a private medical device company in Europe in 2017. The Series C financing will support continuation of clinical activities and acceleration of product and market development for the company’s novel aortic and pulmonary valve programs.
“This robust financing provides us with the resources necessary to catapult our strategy forward – supporting quick expansion of our aortic and pulmonary valve programs and strengthening our quest to redefine heart valve replacement therapy,” said Xeltis Chief Executive Officer (CEO) Laurent Grandidier.
Read the full release here, and learn more about ‘Xeltis’ ongoing program’:
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.